CY1112655T1 - Γλυκοζυλιωμενη ιl-7, παρασκευη και χρησεις - Google Patents
Γλυκοζυλιωμενη ιl-7, παρασκευη και χρησειςInfo
- Publication number
- CY1112655T1 CY1112655T1 CY20121100161T CY121100161T CY1112655T1 CY 1112655 T1 CY1112655 T1 CY 1112655T1 CY 20121100161 T CY20121100161 T CY 20121100161T CY 121100161 T CY121100161 T CY 121100161T CY 1112655 T1 CY1112655 T1 CY 1112655T1
- Authority
- CY
- Cyprus
- Prior art keywords
- polypeptides
- well
- relates
- preparation
- cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5418—IL-7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- AIDS & HIV (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Η παρούσα εφεύρεση αφορά σε νέα και βελτιωμένα πολυπεπτίδια ιντερλευκίνης-7, καθώς επίσης συνθέσεις που περιλαμβάνουν αυτά, παρασκευή αυτών και χρήσεις αυτών. Η εφεύρεση ειδικότερα αφορά σε υπεργλυκοζυλιωμένα ΙL-7 πολυπεπτίδια που έχουν βελτιωμένες ιδιότητες, καθώς επίσης τη βιομηχανική κατασκευή αυτών και θεραπευτικές χρήσεις αυτών. Η εφεύρεση επίσης αποκαλύπτει νέα πολυπεπτίδια IL-7 που έχουν τροποποιημένες αλληλουχίες αμινοξέος που περιέχουν τεχνητώς δημιουργούμενη θέση(-εις) γλυκοζυλίωσης, καθώς επίσης αντίστοιχα μόρια νουκλεϊνικού οξέος, φορείς και ανασυνδυασμένα κύτταρα ξενιστές. Η εφεύρεση επίσης αφορά στη χρήση τέτοιων πολυπεπτιδίων, κυττάρων ή νουκλεϊνικών οξέων για θεραπευτική ή προληπτική θεραπεία υποκειμένων θηλαστικών, συμπεριλαμβανομένων ανθρώπινων υποκειμένων.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05291556A EP1746161A1 (en) | 2005-07-20 | 2005-07-20 | Glycosylated IL-7, preparation and uses |
EP06795556A EP1904635B1 (en) | 2005-07-20 | 2006-07-19 | Glycosylated il-7, preparation and uses |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1112655T1 true CY1112655T1 (el) | 2016-02-10 |
Family
ID=35385570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20121100161T CY1112655T1 (el) | 2005-07-20 | 2012-02-16 | Γλυκοζυλιωμενη ιl-7, παρασκευη και χρησεις |
Country Status (20)
Country | Link |
---|---|
US (3) | US7708985B2 (el) |
EP (2) | EP1746161A1 (el) |
JP (2) | JP5685363B2 (el) |
CN (2) | CN105647939A (el) |
AT (1) | ATE542901T1 (el) |
AU (1) | AU2006271315B2 (el) |
CA (2) | CA2615562C (el) |
CY (1) | CY1112655T1 (el) |
DK (1) | DK1904635T3 (el) |
EA (1) | EA012802B1 (el) |
ES (1) | ES2379732T3 (el) |
HK (1) | HK1115154A1 (el) |
IL (1) | IL188480A0 (el) |
NO (1) | NO344802B1 (el) |
NZ (1) | NZ564907A (el) |
PL (1) | PL1904635T3 (el) |
PT (1) | PT1904635E (el) |
SI (1) | SI1904635T1 (el) |
WO (1) | WO2007010401A2 (el) |
ZA (1) | ZA200800533B (el) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001296962A1 (en) | 2000-09-29 | 2002-04-08 | Schering Corporation | Pegylated interleukin-10 |
EP1391513A1 (en) | 2002-08-08 | 2004-02-25 | Cytheris | IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof |
EP2821078B1 (en) | 2006-09-28 | 2016-09-21 | Merck Sharp & Dohme Corp. | Pegylated il-10 for use in treating lymphoma |
CL2007003411A1 (es) * | 2006-11-28 | 2008-07-04 | Centelion | Proteina fusion que consiste en una region fc de una inmunoglobulina con un fragmento o dominio soluble de un receptor para fgf; polinucleotido que la codifica y vector y celula que lo comprenden; composicion farmaceutica que comprende la proteina fu |
CN101943688B (zh) * | 2009-07-10 | 2013-01-02 | 复旦大学 | 一种利用质谱靶板富集糖基化肽段的方法 |
WO2011150454A1 (en) | 2010-06-01 | 2011-12-08 | Monash University | ANTIBODIES DIRECTED TO THE UNPROCESSED RECEPTOR TYROSINE KINASE c-MET |
CN103140498B (zh) * | 2010-07-19 | 2017-05-17 | 奥塔哥创新有限公司 | 信号生物标志物 |
WO2012058726A1 (en) | 2010-11-05 | 2012-05-10 | Transbio Ltd | Markers of endothelial progenitor cells and uses thereof |
EP2649094B1 (en) | 2010-12-10 | 2016-04-27 | University of Central Florida Research Foundation, Inc. | Methods and compositions comprising il-7 receptor ligands |
ES2568755T3 (es) | 2011-08-03 | 2016-05-04 | Cytheris | Inmunoterapia para VHC |
WO2014172392A1 (en) | 2013-04-18 | 2014-10-23 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
ES2688206T3 (es) | 2013-06-17 | 2018-10-31 | Armo Biosciences, Inc. | Procedimiento de evaluación de la identidad y la estabilidad de proteínas |
EP3068425B1 (en) | 2013-11-11 | 2021-01-27 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
CN104725484B (zh) * | 2013-12-19 | 2018-03-13 | 中国科学院微生物研究所 | 一种糖基化多肽及其制备方法和其应用 |
US20180028593A1 (en) | 2014-03-21 | 2018-02-01 | Boreal Invest | Terminal nanofiltration of solubilized protein compositions for removal of immunogenic aggregates |
WO2015187295A2 (en) | 2014-06-02 | 2015-12-10 | Armo Biosciences, Inc. | Methods of lowering serum cholesterol |
CA2963995A1 (en) | 2014-10-22 | 2016-04-28 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
CN104372021A (zh) * | 2014-11-05 | 2015-02-25 | 太仓思源生物医药有限公司 | 人白细胞介素-2蛋白质的制备方法 |
WO2016126615A1 (en) | 2015-02-03 | 2016-08-11 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
CN107847583A (zh) | 2015-05-28 | 2018-03-27 | 阿尔莫生物科技股份有限公司 | 用于治疗癌症的聚乙二醇化白细胞介素‑10 |
JP2018518955A (ja) * | 2015-06-11 | 2018-07-19 | ジェネクシン・インコーポレイテッドGenexine, Inc. | 改変されたインターロイキン−7タンパク質およびその使用 |
CA3002741A1 (en) | 2015-10-23 | 2017-04-27 | Apogenix Ag | Single-chain gitr-receptor agonist proteins |
KR102386735B1 (ko) | 2015-11-06 | 2022-04-14 | 주식회사 제넥신 | 변형된 인터루킨-7 융합 단백질의 제형 |
US11708399B2 (en) | 2015-12-04 | 2023-07-25 | Genexine, Inc. | Pharmaceutical composition comprising immunoglobulin Fc-fused interleukin-7 fusion protein for preventing or treating human papillomavirus-caused diseases |
CN108697764A (zh) | 2015-12-04 | 2018-10-23 | 格纳西尼有限公司 | 含有免疫球蛋白fc融合白细胞介素-7融合蛋白的用于预防或治疗流感病毒感染的药物组合物 |
CN106317226B (zh) * | 2016-08-19 | 2017-09-05 | 安源医药科技(上海)有限公司 | 用于构建融合蛋白的连接肽 |
MX2020005193A (es) * | 2018-01-25 | 2020-08-20 | I Mab Biopharma Us Ltd | Fusiones de anticuerpo anti-pd-l1 e il-7. |
US20220008515A1 (en) | 2018-11-16 | 2022-01-13 | Neoimmunetech, Inc. | Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor |
WO2020127377A1 (en) | 2018-12-21 | 2020-06-25 | Ose Immunotherapeutics | Bifunctional anti-pd-1/il-7 molecule |
KR102402276B1 (ko) * | 2019-11-15 | 2022-05-26 | 주식회사 제넥신 | 변형된 인터루킨-7 및 tgf 베타 수용체 ii를 포함하는 융합단백질 및 이의 용도 |
WO2021146191A1 (en) | 2020-01-13 | 2021-07-22 | Neoimmunetech, Inc. | Method of treating a tumor with a combination of il-7 protein and a bispecific antibody |
JP2023512657A (ja) | 2020-02-05 | 2023-03-28 | ワシントン・ユニバーシティ | Il-7タンパク質とcar保有免疫細胞の組み合わせで固形腫瘍を治療する方法 |
EP4232070A1 (en) | 2020-10-26 | 2023-08-30 | NeoImmuneTech, Inc. | Methods of inducing stem cell mobilization |
US20240101629A1 (en) | 2020-11-02 | 2024-03-28 | Neoimmunetech, Inc. | Use of interleukin-7 for the treatment of coronavirus |
EP4240408A1 (en) | 2020-11-05 | 2023-09-13 | Neoimmunetech, Inc. | Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine |
WO2022117569A1 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer |
CN113817043B (zh) * | 2021-09-22 | 2023-07-25 | 清华大学 | 制备活性铁调节激素的方法 |
WO2023130081A1 (en) | 2021-12-30 | 2023-07-06 | Neoimmunetech, Inc. | Method of treating a tumor with a combination of il-7 protein and vegf antagonist |
WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
WO2024102722A1 (en) | 2022-11-07 | 2024-05-16 | Neoimmunetech, Inc. | Methods of treating a tumor with an unmethylated mgmt promoter |
WO2024150158A1 (en) | 2023-01-11 | 2024-07-18 | Bright Peak Therapeutics Ag | Il-7 polypeptides, immunocytokines comprising same, and uses thereof |
CN117050178B (zh) * | 2023-10-13 | 2024-01-12 | 北京百普赛斯生物科技股份有限公司 | 特异性检测il-7的抗体及应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
US5328988A (en) * | 1987-10-26 | 1994-07-12 | Immunex Corporation | Interleukin-7 |
ZA887773B (en) | 1987-10-26 | 1989-07-26 | Immunex Corp | Interleukin-7 |
US5714585A (en) * | 1987-10-26 | 1998-02-03 | Sterling Winthrop, Inc. | Antibodies that are immunoreactive with interleukin-7 |
US5153310A (en) * | 1989-02-28 | 1992-10-06 | Du Pont Merck Pharmaceutical Company | Il-2 analogs containing n-linked glycosylation sites |
WO2002002597A2 (en) * | 2000-06-30 | 2002-01-10 | Maxygen Aps | Peptide extended glycosylated polypeptides |
EP1391513A1 (en) | 2002-08-08 | 2004-02-25 | Cytheris | IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof |
-
2005
- 2005-07-20 EP EP05291556A patent/EP1746161A1/en not_active Withdrawn
-
2006
- 2006-07-19 CN CN201610038940.9A patent/CN105647939A/zh active Pending
- 2006-07-19 ES ES06795556T patent/ES2379732T3/es active Active
- 2006-07-19 EP EP06795556A patent/EP1904635B1/en active Active
- 2006-07-19 US US11/996,176 patent/US7708985B2/en active Active
- 2006-07-19 PL PL06795556T patent/PL1904635T3/pl unknown
- 2006-07-19 PT PT06795556T patent/PT1904635E/pt unknown
- 2006-07-19 CA CA2615562A patent/CA2615562C/en active Active
- 2006-07-19 AT AT06795556T patent/ATE542901T1/de active
- 2006-07-19 WO PCT/IB2006/002663 patent/WO2007010401A2/en active Application Filing
- 2006-07-19 JP JP2008522097A patent/JP5685363B2/ja active Active
- 2006-07-19 CA CA2859145A patent/CA2859145C/en active Active
- 2006-07-19 DK DK06795556.7T patent/DK1904635T3/da active
- 2006-07-19 CN CN200680026503.XA patent/CN101228275B/zh active Active
- 2006-07-19 SI SI200631263T patent/SI1904635T1/sl unknown
- 2006-07-19 NZ NZ564907A patent/NZ564907A/en not_active IP Right Cessation
- 2006-07-19 EA EA200800368A patent/EA012802B1/ru not_active IP Right Cessation
- 2006-07-19 AU AU2006271315A patent/AU2006271315B2/en active Active
-
2007
- 2007-12-27 IL IL188480A patent/IL188480A0/en active IP Right Grant
-
2008
- 2008-01-03 NO NO20080045A patent/NO344802B1/no not_active IP Right Cessation
- 2008-01-18 ZA ZA200800533A patent/ZA200800533B/xx unknown
- 2008-04-30 HK HK08104792.4A patent/HK1115154A1/xx not_active IP Right Cessation
-
2010
- 2010-02-24 US US12/711,675 patent/US8034327B2/en active Active
-
2011
- 2011-08-24 US US13/216,331 patent/US8153114B2/en active Active
-
2012
- 2012-02-16 CY CY20121100161T patent/CY1112655T1/el unknown
-
2014
- 2014-10-01 JP JP2014202828A patent/JP2015057392A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1112655T1 (el) | Γλυκοζυλιωμενη ιl-7, παρασκευη και χρησεις | |
ES2353814T3 (es) | Proteinas n-glicosiladas recombinantes de celulas procariotas. | |
MX2009012650A (es) | Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos. | |
ATE454403T1 (de) | Menschliche koagulationsfaktor vii polypeptide | |
MX2010005783A (es) | Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas. | |
MX2008001865A (es) | Proteinas de fusion de albumina. | |
MX2009002816A (es) | Proteinas de fusion de albumina. | |
MX362028B (es) | Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos. | |
WO2007104529A3 (en) | Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling | |
MX2009004243A (es) | Nuevas proteinas h5, moleculas de acido nucleico y vectores que las codifican y su uso medicinal. | |
DE60027409D1 (de) | Glykosylierte leptinzusammensetzungen und zugehörige verfahren | |
IL212653A0 (en) | Polypeptides of leishmania major and polynucleotides encoding same and vaccinal, therapeutical and diagnostic applications thereof | |
ATE501728T1 (de) | Therapeutische verwendung von lpi, einem inhibitor des lectinwegs in staphylokokken bei entzündungskrankheiten | |
BR0308180A (pt) | protéinas de superfìcie de leptospira | |
ATE484520T1 (de) | Antitumorheilmittel, medikament, zusammensetzung und verwendung davon |